Exact Sciences schedules third quarter 2022 earnings call
Exact Sciences Corp. (Nasdaq: EXAS) announced the release of its third quarter 2022 financial results, scheduled for November 3, 2022, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) announced the release of its third quarter 2022 financial results, scheduled for November 3, 2022, after U.S. market close. Management will discuss the results and business updates during a webcast at 5 p.m. ET the same day. Investors can access the live webcast through the company's website. Exact Sciences focuses on cancer screening and diagnostics, leveraging products like Cologuard® and Oncotype®. Further information can be found on their official site.
Details
News Market Reaction – EXAS
The recorded move for EXAS in the trading session of this news was -3.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MADISON, Wis., Oct. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Third quarter 2022 webcast & conference call details
Date: | Thursday, November 3, 2022 |
Time: | 5 p.m. ET |
Webcast: | The live webcast can be accessed at www.exactsciences.com |
Telephone: | Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 | |
Access code for both domestic and international callers: 4437608 |
An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-770-2030 domestically or +1 647-362-9199 internationally. The access code for the replay of the call is 4437608. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.
Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-schedules-third-quarter-2022-earnings-call-301644408.html
SOURCE Exact Sciences Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.